Treatment of chronic kidney disease in older populations

Seiji Kishi1, Hiroyuki Kadoya2, Naoki Kashihara3,4

  • 1Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.

PubMed

Insights

Managing chronic kidney disease (CKD) in aging populations requires integrated strategies. Emerging therapies and patient-centered approaches are key to improving outcomes and quality of life for older adults with CKD.

Area of Science:

  • Nephrology
  • Geriatrics
  • Public Health

Background:

  • Global population aging is increasing chronic kidney disease (CKD) prevalence in older adults.
  • CKD management in the elderly presents significant healthcare resource challenges.
  • Standard CKD treatment goals include reducing cardiovascular events and kidney failure progression.

Purpose of the Study:

  • To outline effective management strategies for CKD in the aging population.
  • To highlight the role of emerging pharmacotherapies and non-pharmacological interventions.
  • To emphasize patient-centered decision-making for kidney replacement therapy.

Main Methods:

  • Review of current treatment guidelines and emerging therapies for CKD in older adults.
  • Discussion of non-pharmacological interventions like nutrition and exercise.
  • Exploration of factors influencing kidney replacement therapy decisions.
  • Consideration of digital health integration in CKD management.

Main Results:

  • SGLT-2 inhibitors and GLP-1 receptor agonists show promise for CKD management in the elderly.
  • Nutritional and exercise therapies complement pharmacotherapy, improving quality of life and cognitive function.
  • Individualized, patient-centered approaches are crucial for kidney replacement therapy decisions.
  • Digital technologies offer potential for transforming CKD care in aging populations.

Conclusions:

  • Integrated management strategies combining pharmacotherapy, non-pharmacological interventions, and patient-centered care are essential for older adults with CKD.
  • Emerging therapies and digital health integration hold significant potential for improving CKD outcomes in the aging demographic.
  • Tailored treatment plans, considering individual factors beyond age and cognition, are paramount for kidney failure management.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
288
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
74
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177